Skip to content
Screener

Castle Biosciences CSTL Q4 2025 Annual earnings

Reported February 26, 2026 · After market close

Revenue$87.0MBeat by $7.1M
EPS-$0.08Beat by $0.15
Revenue estimate$79.9M
EPS estimate-$0.23

Next report

Nov 2, 2026 (in a month)
Revenue estimate$92.1M
EPS estimate-$0.38

Financials

Q4 2025

Income statement

See full
Revenue$87.0M+0.8%
Gross profit$68.7M-2.0%
Operating income-$3.8M-194%
Net income-$2.3M-124%
EPS (diluted)-$0.07-122%

Balance sheet

See full
Cash & equivalents$116.7M-2.5%
Total debt$37.0M+40.0%
Total equity$470.9M+3.3%
Total assets$578.6M+8.9%

Cash flow

See full
Operating cash flow$26.9M+10.5%
CapEx$7.2M-5.1%
Free cash flow$19.7M+17.6%

Valuation & ratios

Valuation

as of 12/31/25
See full
Market cap$1.14B+52.1%
Enterprise value$1.06B+61.6%
P/S3.3×+1.1×

Profitability

See full
Gross margin79.4%-2.5pp
Operating margin-12.4%-15.0pp
Net margin-7%-12.5pp
FCF margin8.2%-2.8pp

Returns & leverage

See full
Return on equity-5.2%-9.5pp
Debt / equity0.1×0.0×
Current ratio5.3×-2.0×

Segments

By product

See full
Dermatologic$48.6M-23.8%
Non-Dermatologic$38.4M+70.5%

By segment

See full
Reportable Segment$87.0M+0.8%

FAQ

When did Castle Biosciences report Q4 2025 earnings?
Castle Biosciences (CSTL) reported Q4 2025 earnings on February 26, 2026 after market close.
What were Castle Biosciences's Q4 2025 revenue and EPS?
Castle Biosciences reported revenue of $87.0M and eps of $-0.08 for Q4 2025.
Did Castle Biosciences beat estimates in Q4 2025?
Revenue beat the consensus estimate of $79.9M by $7.1M. EPS beat the consensus estimate of $-0.23 by $0.15.
How did Castle Biosciences's Q4 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 0.8% from $86.3M a year earlier.
Where can I find Castle Biosciences's Q4 2025 SEC filings?
You can read the 8-K earnings release (0001628280-26-012263) and the 10-K periodic report (0001628280-26-012272) directly on SEC EDGAR. The filing index links above go to sec.gov.